Molecule Med is a science-driven biotechnology company pioneering the next wave of regenerative medicine by fusing advanced biologics, cell therapies, and biomimetic scaffolds to reshape the way clinicians deliver care. Our mission is to empower medical professionals with innovative solutions that accelerate healing, restore tissue integrity, and optimize patient outcomes. Currently, we are developing a cutting-edge biodegradable biomimetic scaffold, , designed specifically for chronic and non-healing wounds.
By combining our proprietary scaffold with exosome-based biologics, offers new hope for faster, more effective healing—including in diabetic wounds.
Dato’ Alvin began his career in Sales and Marketing, spending over 17 years developing global sales strategies and establishing a strong presence in key international markets across Hong Kong, China, the Americas, Europe, and Asia Pacific. His early success in driving growth and building international networks laid a solid foundation for his role as a transformative leader in healthcare and biotechnology. He served as Executive Director of a Bursa Malaysia–listed company, successfully turning around the business by establishing Malaysia’s first commercial BSL-2 cGMP cell manufacturing laboratory.
As the inventor and patent holder of ExoMesh, Jeysie is involved from the very beginning — ensuring every step of R&D is aligned with real market needs. ExoMesh features a fibrous scaffold with a three-dimensional topological structure, offering clear clinical differentiation and a strong IP moat. All patent rights have been exclusively entrusted to Molecule Med, ensuring professional global IP management and strategic protection.
Dato’ Ken Low is a preeminent investor, strategic business advisor, and chartered accountant, whose distinguished career spans executive and board leadership across diverse, high-growth sectors including healthcare, biotechnology, finance, agriculture, and logistics, both in Malaysia and internationally. His exceptional financial acumen is underscored by his status as a Fellow Member of the Association of Chartered Certified Accountants, the Malaysian Institute of Accountants, and the ASEAN Chartered Professional Accountant. Notably, Dato’ Ken Low brings this profound expertise to the global stage as a vital part of the board of Emmis Acquisition Corp., a special purpose acquisition company listed on NASDAQ:EMIS, which recently announced a closing of USD 115,000,000 Initial Public Offering, affirming his position in international capital markets and strategic corporate governance.
